Rahul Mehan, MD

Rahul Mehan, MD, explains when traditional resective procedures still make more sense than office-based options, shares his top advice for urologists early in adoption, and previews the minimally invasive technologies he's watching next.

Two years into offering drug-coated balloon dilation for BPH, Rahul Mehan, MD, compares his outcomes with the PINNACLE trial (NCT04131907), walks through sizing and patient selection, and details the recovery and safety counseling patients need before treatment.

Rahul Mehan, MD, explains why patients are pushing back on daily BPH medication, how prostate anatomy shapes the choice between mechanical, thermal, and drug-coated therapies, and what's fueling the shift to office-based care.

In this video, part 5 in a 5-part series, panelists examine the economic and logistical realities of bringing mitomycin for intravesical solution (Zusduri; formerly UGN-102) into private practice.

In this video, part 4 in a 5-part series, Nick Liu, MD, outlines key scenarios where surgical resection remains preferred for treating LG-IR-NMIBC.

In this video, part 3 in a 5-part series, panelists discuss the long-term clinical impact and health care system implications of mitomycin for intravesical solution (Zusduri; formerly UGN-102).

In this video, part 2 in a 5-part series, Nick Liu, MD, breaks down the formulation behind mitomycin for intravesical solution (Zusduri; formerly UGN-102).

In this video, part 1 in a 5-part series, panelists discuss how mitomycin for intravesical solution (formerly UGN-102, now marketed as Zusduri) fits into the evolving management landscape for recurrent bladder tumors.